{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:21:03Z","timestamp":1791231663322,"version":"4.1.0"},"reference-count":37,"publisher":"Japanese Circulation Society","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2023,7,7]]},"DOI":"10.1253\/circj.cj-23-0211","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T18:14:43Z","timestamp":1688667283000},"source":"Crossref","is-referenced-by-count":11,"title":["Demographic Traits, Clinical Status, and Comorbidities of Patients With Thromboangiitis Obliterans in Japan"],"prefix":"10.1253","author":[{"given":"Yoshiko","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of General Medicine, Kawasaki Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Iwahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, International University of Health and Welfare, Mita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Nakaoka","sequence":"additional","affiliation":[{"name":"Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shionoya S. Diagnostic criteria of Buerger\u2019s disease. <i>Int J Cardiol<\/i> 1998; 66(Suppl 1): S243\u2013S247.","DOI":"10.1016\/S0167-5273(98)00175-2"},{"key":"2","unstructured":"2. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger\u2019s disease). <i>Circulation<\/i> 1990; 82: IV3\u2013IV8."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Watanabe Y, Miyata T, Shigematsu K, Tanemoto K, Nakaoka Y, Harigai M. Current trends in epidemiology and clinical features of thromboangiitis obliterans in Japan: A nationwide survey using the medical support system database. <i>Circ J<\/i> 2020; 84: 1786\u20131796.","DOI":"10.1253\/circj.CJ-19-1165"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Choi B, Jang SY, Kim SK, Kim N, Kim K, Kim DK. The incidence, prevalence, and survival rate of thromboangiitis obliterans in Korea: A retrospective population-based study. <i>Cardiovasc Diagn Ther<\/i> 2020; 10: 1238\u20131244.","DOI":"10.21037\/cdt-20-582"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Zheng JF, Chen YM, Chen DY, Lin CH, Chen HH. The incidence and prevalence of thromboangiitis obliterans in Taiwan: A nationwide, population-based analysis of data collected from 2002 to 2011. <i>Clinics (Sao Paulo)<\/i> 2016; 71: 399\u2013403, doi:10.6061\/clinics\/2016(07)08.","DOI":"10.6061\/clinics\/2016(07)08"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Olin JW. Thromboangiitis obliterans (Buerger\u2019s disease). <i>N Engl J Med<\/i> 2000; 343: 864\u2013869.","DOI":"10.1056\/NEJM200009213431207"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sun XL, Law BY, de Seabra Rodrigues Dias IR, Mok SWF, He YZ, Wong VK. Pathogenesis of thromboangiitis obliterans: Gene polymorphism and immunoregulation of human vascular endothelial cells. <i>Atherosclerosis<\/i> 2017; 265: 258\u2013265.","DOI":"10.1016\/j.atherosclerosis.2017.08.009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mills JL, Porter JM. Buerger\u2019s disease (thromboangiitis obliterans). <i>Ann Vasc Surg<\/i> 1991; 5: 570\u2013572.","DOI":"10.1007\/BF02015288"},{"key":"9","unstructured":"9. Papa M, Bass A, Adar R, Halperin Z, Schneiderman J, Becker CG, et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger\u2019s disease): The role of tobacco antigen and the major histocompatibility complex. <i>Surgery<\/i> 1992; 111: 527\u2013531."},{"key":"10","unstructured":"10. Shigematsu H, Shigematsu K. Factors affecting the long-term outcome of Buerger\u2019s disease (thromboangiitis obliterans). <i>Int Angiol<\/i> 1999; 18: 58\u201364."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Le Joncour A, Soudet S, Dupont A, Espitia O, Koskas F, Cluzel P, et al. Long-term outcome and prognostic factors of complications in thromboangiitis obliterans (Buerger\u2019s disease): A multicenter study of 224 patients. <i>J Am Heart Assoc<\/i> 2018; 7: e010677.","DOI":"10.1161\/JAHA.118.010677"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Joviliano EE, Dellalibera-Joviliano R, Dalio M, Evora PR, Piccinato CE. Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans: Current practices. <i>Int J Angiol<\/i> 2009; 18: 119\u2013125.","DOI":"10.1055\/s-0031-1278337"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lee T, Seo JW, Sumpio BE, Kim SJ. Immunobiologic analysis of arterial tissue in Buerger\u2019s disease. <i>Eur J Vasc Endovasc Surg<\/i> 2003; 25: 451\u2013457.","DOI":"10.1053\/ejvs.2002.1869"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kobayashi M, Sugimoto M, Komori K. Endarteritis obliterans in the pathogenesis of Buerger\u2019s disease from the pathological and immunohistochemical points of view. <i>Circ J<\/i> 2014; 78: 2819\u20132826.","DOI":"10.1253\/circj.CJ-14-0656"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Iwai T, Umeda M, Inoue Y. Are there any objections against our hypothesis that Buerger disease is an infectious disease? <i>Ann Vasc Dis<\/i> 2012; 5: 300\u2013309.","DOI":"10.3400\/avd.ra.12.00032"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Igari K, Kudo T, Toyofuku T, Inoue Y. Endothelial dysfunction in patients with Buerger disease. <i>Vasc Health Risk Manag<\/i> 2017; 13: 317\u2013323.","DOI":"10.2147\/VHRM.S139892"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Piazza G, Creager MA. Thromboangiitis obliterans. <i>Circulation<\/i> 2010; 121: 1858\u20131861.","DOI":"10.1161\/CIRCULATIONAHA.110.942383"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hida N, Ohta T. Current status of patients with Buerger disease in Japan. <i>Ann Vasc Dis<\/i> 2013; 6: 617\u2013623.","DOI":"10.3400\/avd.oa.13-00012"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger disease. <i>J Vasc Surg<\/i> 2004; 39: 176\u2013180.","DOI":"10.1016\/j.jvs.2003.08.006"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger\u2019s disease) in Japan. <i>Int J Cardiol<\/i> 2000; 75(Suppl 1): S175\u2013S181.","DOI":"10.1016\/S0167-5273(00)00190-X"},{"key":"21","unstructured":"21. Borner C, Heidrich H. Long-term follow-up of thromboangiitis obliterans. <i>Vasa<\/i> 1998; 27: 80\u201386."},{"key":"22","unstructured":"22. Japan Intractable Diseases Information Center. The database of the number of recipient certificates issued for specific disease treatment. https:\/\/www.nanbyou.or.jp\/entry\/1356 (accessed August 15, 2022)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Cooper LT, Tse TS, Mikhail MA, McBane RD, Stanson AW, Ballman KV. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger\u2019s disease). <i>J Am Coll Cardiol<\/i> 2004; 44: 2410\u20132411.","DOI":"10.1016\/j.jacc.2004.09.029"},{"key":"24","unstructured":"24. Statistics Japan. Labour Force Survey, Historical data 1 b-5 Labour force participation rate [by age group]: Whole Japan, Monthly Data. https:\/\/www.stat.go.jp\/data\/roudou\/longtime\/03roudou.html (accessed August 15, 2022)."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sugimoto M, Miyachi H, Morimae H, Kodama A, Narita H, Banno H, et al. The fate of ischemic limbs in patients with Buerger\u2019s disease based on our 30-year experience: Does smoking have a definitive impact on the late loss of limbs? <i>Surg Today<\/i> 2015; 45: 466\u2013470.","DOI":"10.1007\/s00595-014-0904-6"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Iwai T, Kume H, Koizumi S, Sakurazawa K, Honma K, Ogasawara H, et al. Buerger disease: Pathological changes in elderly patients. <i>Ann Vasc Dis<\/i> 2022; 15: 29\u201336.","DOI":"10.3400\/avd.oa.21-00142"},{"key":"27","unstructured":"27. Japanese Ministry of Health, Labour and Welfare. Status of the number of patients with cerebrovascular disease. Annual Health, Labour and Welfare Report 2017. https:\/\/www.mhlw.go.jp\/stf\/wp\/hakusyo\/kousei\/18\/backdata\/01-01-02-04.html (accessed August 15, 2022)."},{"key":"28","unstructured":"28. Statistics Bureau of Japan. Population estimates by age [five-year groups] and sex in 2017 (in Japanese). https:\/\/www.stat.go.jp\/data\/jinsui\/pdf\/201712.pdf (accessed August 15, 2022)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Mills JL Sr. Buerger\u2019s disease in the 21st century: Diagnosis, clinical features, and therapy. <i>Semin Vasc Surg<\/i> 2003; 16: 179\u2013189.","DOI":"10.1016\/S0895-7967(03)00023-1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Fakour F, Fazeli B. Visceral bed involvement in thromboangiitis obliterans: A systematic review. <i>Vasc Health Risk Manag<\/i> 2019; 15: 317\u2013353.","DOI":"10.2147\/VHRM.S182450"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kurata A, Nonaka T, Arimura Y, Nunokawa M, Terado Y, Sudo K, et al. Multiple ulcers with perforation of the small intestine in Buerger\u2019s disease: A case report. <i>Gastroenterology<\/i> 2003; 125: 911\u2013916.","DOI":"10.1016\/S0016-5085(03)01065-5"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Mishra SS, Mishra TS, Mitra S, Kumar P. Intestinal thromboangiitis obliterans: A case report. <i>J Med Case Rep<\/i> 2021; 15: 1\u20137.","DOI":"10.1186\/s13256-021-02719-3"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Shionoya S. Buerger\u2019s disease: Diagnosis and management. <i>Cardiovasc Surg<\/i> 1993; 1: 207\u2013214.","DOI":"10.1177\/096721099300100302"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger\u2019s disease. <i>Eur J Vasc Endovasc Surg<\/i> 1996; 11: 335\u2013339.","DOI":"10.1016\/S1078-5884(96)80081-5"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Soudet S, Le Joncour A, Quemeneur T, Maillard H, Koskas F, Hachulla E, et al. Did the clinical spectrum of thromboangiitis obliterans change in the past 40 years? <i>Angiology<\/i> 2020; 71: 621\u2013625.","DOI":"10.1177\/0003319720920163"},{"key":"36","unstructured":"36. Shapouri-Moghaddam A, Saeed Modaghegh MH, Rahimi HR, Ehteshamfar SM, Tavakol Afshari J. Molecular mechanisms regulating immune responses in thromboangiitis obliterans: A comprehensive review. <i>Iran J Basic Med Sci<\/i> 2019; 22: 215\u2013224."},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Fazeli B, Ligi D, Keramat S, Maniscalco R, Sharebiani H, Mannello F. Recent updates and advances in Winiwarter-Buerger disease (thromboangiitis obliterans): Biomolecular mechanisms, diagnostics and clinical consequences. <i>Diagnostics (Basel)<\/i> 2021; 11: 1736, doi:10.3390\/diagnostics11101736.","DOI":"10.3390\/diagnostics11101736"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/advpub\/0\/advpub_CJ-23-0211\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T23:15:36Z","timestamp":1688771736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/advpub\/0\/advpub_CJ-23-0211\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1253\/circj.cj-23-0211","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"article-number":"CJ-23-0211"}}